Investor Update

Basel, 19 December 2018

Chugai’s Satralizumab Meets Primary Endpoint in Phase III Monotherapy Study in NMOSD

Dear Investor,

Please find attached a press release by Chugai.

Do not hesitate to contact us for any further questions.